

Table I. Study and patient characteristics of included studies

Study	Study design – Country	Study duration	Sample size, n	Sex (female, %)	Age, years Mean (SD) [range]	Duration of spasticity, years Mean (SD) [range]	Severity of spasticity	Baclofen dosage (mg/day)	
<i>Baclofen vs placebo</i>									
Multiple sclerosis									
Hudgson & Weightman, 1971 (31)	Crossover – UK	10 days	23	30.4	30–63	—	Severe	30	
Duncan et al., 1976 (25)	Crossover – USA	4 weeks	25	50	36.4	—	—	15–100	
Sachais et al., 1977 (30)	Parallel – USA	BAC PLA	5 weeks	85	57.4	43 [20–64]	10.6 [7 months–31]	—	Outpatients 15–80
			81	61.5	43 [21–65]	11.2 [8 months–29]	Inpatients 30–80		
Feldman et al., 1978 (26)	Crossover – USA	10 weeks	33	—	43 [38–53]	15.3 [3–30]	—	15–80	
Sawa & Paty, 1979 (27)	Crossover – Canada	21 days	21	76.3	24–54	12.6 [est.]	—	15–60	
Brar et al., 1991 (32)	Crossover – USA	10 weeks	38	76.3	24–54	—	Mild-to-moderate	15–20	
Ørsnes et al., 2000 (46)	Crossover – Denmark	11 days	14	64.3	43.4 (9.1)	—	Moderate	15–45	
Cerebral palsy									
Milla & Jackson, 1977 (28)	RCT-crossover – UK	4 weeks	20	55	2–16	—	Moderate	10–60 (30–40 for children 2–7 years)	
McKinley et al., 1980 (33)	RCT-crossover – UK	4 weeks	20	50	7–16	—	—	0.5 mg/kg/day – 60 mg/day	
Stroke									
Medaer et al., 1991 (29)	RCT-crossover – Belgium	4 weeks	20	65	64.9 (16.4)	4 [1 months–13 years]	Severe	10–50	
<i>Baclofen vs active comparators or open-label</i>									
Multiple sclerosis									
Baclofen vs tizanidine									
Smolenski et al., 1981 (34)	Parallel – Switzerland	BAC	10	50	55.0 (10.0) [42–73]	26.6 (8.0)	Moderate-to-severe	10–80	
		TIZ	11	55	53.0 (11.0) [40–69]	17.3 (10.0)			
Newman et al., 1982 (35)	Crossover – UK	1 month	36	53.8	45.9 (9.4)	9.0 (9.9)	Moderate-to-severe	5–40	
Stien et al., 1987 (36)	Parallel – Norway	BAC	6 weeks	21	60	45 ^a [26–66]	13 ^a [5–33]	Moderate-to-severe	10–90
		TIZ	19	50	50 ^a [29–70]	14 ^a [4–39]	Moderate		
Bass et al., 1988 (44)	Crossover – Canada	5 weeks	62	49.9	51.0 [est.]	8.1 [est.]	Moderate-to-severe	5–80	
Eyssette et al., 1988 (37)	Parallel – France	BAC	8 weeks	50	42	47.5 (1.7)	—	—	16–60
		TIZ	50	44.0	46.8 (1.6)	—			
Hoogstraten et al., 1988 (38)	Crossover – Holland	4 weeks	16	37.5	54.9 (8.3) [34–67]	—	Moderate	15–60	
Baclofen vs diazepam									
Cartlidge et al., 1974 (45)	Crossover – UK	4 weeks	40	47.5	22–61	—	Moderate	30–60	
From & Hudgson, 1975 (43)	Crossover – Denmark	4 weeks	17	62.9	51 [38–68]	—	Moderate	30–120	
Spinal cord injury									
Jones & Lance, 1976 (23)	Open-label – Australia	—	6 years	113	25.7	35 [6–68]	—	—	30–200
		BAC	33	0	—	—	Moderate-to-severe	Up to 80	
Nance et al., 1994 (39)	Comparative (crossover) –Canada	3 weeks							
Aydin et al., 2005 (40)	Comparative – Turkey	BAC	8 weeks	10	100	32.7 (16.3)	11.5 (11.7) [4–44]	Moderate-to-severe	5–80
		TENS	11	45.5	29.3 (7.3)	11.5 (13.9) [2–49]			
Cerebral palsy									
Bresolin et al., 2009 (41)	RCT-parallel – Italy	BAC	8 weeks	40	40	52.4 (15.1)	93.7 (90.9) month	Moderate-to-severe	30–60
		EPE	40	37.5	49.8 (13.8)	111.6 (99.3) month			
Brain injury									
Medici et al., 1989 (42)	RCT-parallel – Uruguay	BAC	1 years	15	13.3	49 [24–68]	4.5 [0.5–14]	Moderate-to-severe	20–50
		TIZ	15	26.7	50 [22–73]	2.5 [0.1–10]			
Meythaler et al., 2004 (24)	Open-label –US	3 months	35	37.1	31 [6–86]	—	Severe	5–80	

*Median.

BAC: baclofen; CLO: clonidine; CYP: cyproheptadine; EPE: eperisone; TENS: transcutaneous electrical nerve stimulation; TIZ: tizanidine; PLA: placebo.